Unicycive regains Nasdaq minimum bid price compliance after reverse split

Unicycive Therapeutics, Inc.

Regained compliance with Nasdaq minimum bid price of $1.00 per share.
Nasdaq notified the company on July 7, 2025, confirming compliance as of July 3, 2025.
Compliance achieved after a 1:10 reverse stock split effective June 20, 2025.
The matter is now closed by Nasdaq.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.